A Proof of Concept Study for Preemptive Treatment With Grazoprevir and Elbasvir in Donor HCV-positive to Recipient HCV-negative Cardiac Transplant
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 31 Dec 2018
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Proof of concept; Therapeutic Use
- 18 Dec 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 27 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 1 Aug 2018.
- 27 Dec 2017 Status changed from suspended to not yet recruiting.